Karyopharm Therapeutics Inc.
KPTI institutional ownership changes in Q2 2026: 46 institutions opened or added positions, 13 trimmed or exited. KPTI (Karyopharm Therapeutics Inc.) is held by 59 institutional investors as of Q2 2026. Top institutional shareholders: RA Capital Management, L.P. ($18.7M), Adage Capital Partners GP, L.L.C. ($14.9M), Goldman Sachs Group Inc. ($13.9M). Institutions were buying, on balance.
Who's Trading
Latest move
Source dates: Price Nov 6, 2026 · Insiders Oct 19, 2026 · Activists Oct 28, 2026 · Congress none
Top Holders
| Action | ||||||
|---|---|---|---|---|---|---|
Unchanged | 1.9M | $18.7M | 0.2% | -99.01% | 0 | |
Decreased | 1.5M(-15.8%) | $14.9M | 0.0% | -98.93% | 0 | |
Increased | 1.4M(+50.4%) | $13.9M | 0.0% | -99.21% | 39 | |
Increased | 1.4M(+479.3%) | $13.9M | 0.0% | -99.37% | 45 | |
Increased | 958,979(+29.6%) | $9.4M | 0.0% | -99.16% | 35 | |
Increased | 695,264(+359.7%) | $6.8M | 0.0% | -99.41% | 44 | |
Increased | 531,231(+157.7%) | $5.2M | 0.0% | +19.95% | 44 | |
Increased | 353,545(+82.2%) | $3.5M | 0.0% | -99.25% | 41 | |
Increased | 325,991(+303.7%) | $3.2M | 0.0% | -99.37% | 43 | |
Increased | 309,817(+45.9%) | $3M | 0.0% | -99.20% | 36 | |
Decreased | 305,676(-27.3%) | $3M | 0.0% | -99.01% | 0 | |
Increased | 207,609(+440x) | $2.1M | 0.0% | -99.44% | 42 | |
Increased | 202,506(+990.5%) | $2M | 0.0% | -99.41% | 42 | |
Decreased | 188,368(-27.0%) | $1.8M | 0.0% | -99.06% | 0 | |
Increased | 188,038(+2238x) | $1.8M | 0.0% | -99.44% | 42 | |
Increased | 165,904(+2134.7%) | $1.6M | 0.0% | +2.45% | 41 | |
Increased | 160,006(+315.0%) | $1.6M | 0.0% | -99.37% | 41 | |
Increased | 145,401(+26.5%) | $1.4M | 0.0% | -99.15% | 31 | |
New | 134,818 | $1.3M | 0.0% | -99.44% | 35 | |
Unchanged | 128,451 | $1.3M | 0.0% | -98.53% | 0 |
Showing 1-20 of 65
| Insider | Trade | Traded |
|---|---|---|
| Abate Kristin | Sell $2K | |
| Abate Kristin | Sell $449.82 | |
| Abate Kristin | Sell $38.38 | |
| Poulton Stuart | Sell $1K | |
| Abate Kristin | Sell $5K | |
| Cheng Sohanya Roshan | Sell $43K | |
| Rangwala Reshma | Sell $48K | |
| Paulson Richard A. | Sell $116K | |
| Poulton Stuart | Sell $48K | |
| Mano Michael | Sell $33K |
| Filer | Stake | Filed |
|---|---|---|
| Integrated Core Strategies (US) LLC | 0.2% | |
| Anders Hove | 4.5% | |
| Anders Hove | 5.7% | |
| Anders Hove | 5.7% | |
| Integrated Core Strategies (US) LLC | 5.7% | |
| Commodore Capital LP | 0.0% | |
| RA Capital Management, L.P. | 9.9% | |
| Adage Capital Management, L.P. | 6.8% | |
| THE GOLDMAN SACHS GROUP, INC. | 6.3% | |
| BlackRock, Inc. | 5.6% |
KPTIKaryopharm Therapeutics Inc.Continue exploring
Other Healthcare stocks held by institutions
UNHUnitedHealth Group Incorporated
LLYEli Lilly and Company
TMOThermo Fisher Scientific Inc
JNJJohnson & Johnson
DHRDanaher Corporation
ISRGIntuitive Surgical, Inc.
MRKMerck & Company, Inc.
ABBVAbbVie Inc.
BSXBoston Scientific Corporation
ABTAbbott LaboratoriesQuestions investors ask about KPTI
Who owns KPTI?
59 institutional investors held KPTI on June 30, 2026, led by RA Capital Management, L.P. ($18.7M), Adage Capital Partners GP, L.L.C. ($14.9M) and Goldman Sachs Group Inc. ($13.9M).
How many hedge funds hold KPTI?
59 institutional investors reported KPTI in their 13F filings for the quarter ended June 30, 2026, $121.6M in all. One of them is rated Elite.
Are institutions buying or selling KPTI?
Buying, on balance. In Q2 2026, 46 institutions opened or added to positions in KPTI and 13 institutions trimmed or exited.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer